Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBT Margin: 2020-2025

Historic EBT Margin for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to 13,180.50%.

  • Silence Therapeutics' EBT Margin fell 1081101.00% to 13,180.50% in Q3 2025 from the same period last year, while for Sep 2025 it was 248.57%, marking a year-over-year increase of 17274.00%. This contributed to the annual value of 102.79% for FY2024, which is 6557.00% up from last year.
  • As of Q3 2025, Silence Therapeutics' EBT Margin stood at 13,180.50%, which was down 7.97% from 12,207.14% recorded in Q2 2025.
  • Silence Therapeutics' 5-year EBT Margin high stood at 49.90% for Q4 2024, and its period low was 20,091.55% during Q1 2025.
  • In the last 3 years, Silence Therapeutics' EBT Margin had a median value of 713.01% in 2023 and averaged 4,690.02%.
  • As far as peak fluctuations go, Silence Therapeutics' EBT Margin soared by 76,290bps in 2024, and later crashed by 2,007,838bps in 2025.
  • Silence Therapeutics' EBT Margin (MRQ) stood at 328.85% in 2021, then rose by 4bps to 315.84% in 2022, then tumbled by 126bps to 713.01% in 2023, then surged by 107bps to 49.90% in 2024, then tumbled by 26,516bps to 13,180.50% in 2025.
  • Its last three reported values are 13,180.50% in Q3 2025, 12,207.14% for Q2 2025, and 20,091.55% during Q1 2025.